Cancer – ADVL1823: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Condition or Therapy:
Pediatric Solid Tumors, Relapsed Pediatric Acute Leukemias
Cancer and Blood Disorders
Study Number: ADVL1823
What is the goal of this study?
This study aims to find the effects of a drug or combination of drugs on patients with pediatric solid tumors or relapsed pediatric acute leukemia.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are 30 years of age or younger
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106.